ID: ALA4469821

Max Phase: Preclinical

Molecular Formula: C22H28N4O6S

Molecular Weight: 476.56

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  C[C@@](CCN1Cc2cc(C#CC#CCN3CCC(O)CC3)cn2C1=O)(C(=O)NO)S(C)(=O)=O

Standard InChI:  InChI=1S/C22H28N4O6S/c1-22(20(28)23-30,33(2,31)32)9-13-25-16-18-14-17(15-26(18)21(25)29)6-4-3-5-10-24-11-7-19(27)8-12-24/h14-15,19,27,30H,7-13,16H2,1-2H3,(H,23,28)/t22-/m1/s1

Standard InChI Key:  CCGOILUUXMFWEY-JOCHJYFZSA-N

Associated Targets(non-human)

Escherichia coli (133304 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Klebsiella pneumoniae (43867 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Pseudomonas aeruginosa (123386 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
lpxC UDP-3-O-acyl-GlcNAc deacetylase (448 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
lpxC UDP-3-O-acyl-GlcNAc deacetylase (700 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 476.56Molecular Weight (Monoisotopic): 476.1730AlogP: -0.22#Rotatable Bonds: 6
Polar Surface Area: 132.18Molecular Species: NEUTRALHBA: 8HBD: 3
#RO5 Violations: 0HBA (Lipinski): 10HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: 8.68CX Basic pKa: 7.21CX LogP: -1.43CX LogD: -1.52
Aromatic Rings: 1Heavy Atoms: 33QED Weighted: 0.29Np Likeness Score: -0.25

References

1. Panchaud P, Surivet JP, Diethelm S, Blumstein AC, Gauvin JC, Jacob L, Masse F, Mathieu G, Mirre A, Schmitt C, Enderlin-Paput M, Lange R, Gnerre C, Seeland S, Herrmann C, Locher HH, Seiler P, Ritz D, Rueedi G..  (2020)  Optimization of LpxC Inhibitor Lead Compounds Focusing on Efficacy and Formulation for High Dose Intravenous Administration.,  63  (1): [PMID:31804829] [10.1021/acs.jmedchem.9b01605]

Source